Challenges associated with the use of Bruton's tyrosine kinase inhibitors: A life‑saving therapy for chronic lymphocytic leukemia (Review)

Mihaila,Romeo Gabriel

doi:10.3892/wasj.2024.241

Challenges associated with the use of Bruton's tyrosine kinase inhibitors: A life‑saving therapy for chronic lymphocytic leukemia (Review)

Authors:
- Romeo Gabriel Mihaila
View Affiliations

Affiliations: Department of Hematology, Faculty of Medicine, ‘Lucian Blaga’ University of Sibiu, Sibiu 550169, Romania
Published online on: April 2, 2024 https://doi.org/10.3892/wasj.2024.241
Article Number: 26
Copyright : © Mihaila . This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The adverse effects (AEs) of chemotherapy for chronic lymphocytic leukemia (CLL) can currently be avoided using Bruton's tyrosine kinase inhibitors (BTKis) and/or B‑cell leukemia/lymphoma 2 (BCL2) inhibitors, which have increased the efficacy of therapy and improved the prognosis of patients. The progression‑free survival and overall response rate of patients are significantly longer with the use of BTKis compared with the use of combination therapy. They are standard of care for use as frontline therapy and for the treatment of refractory or relapsed CLL. The use of BTKis is also indicated for patients with active disease and del17p, TP53 mutation, or unmutated immunoglobulin heavy chain genes, for their greater efficacy compared to chemotherapy + anti‑CD20 monoclonal antibodies or BCL2 inhibitors. Ibrutinib inhibits various specific immune receptors, exerts immunomodulatory effects, and some immune manifestations respond to ibrutinib. The main limitations associated with the use of BTKis are the following: The emergence of drug resistance, low complete remission rates, the need for an indefinite treatment duration and possible AEs. The use of ibrutinib is not recommended for patients with ventricular arrhythmias, and the use of any BTKi is not recommended for those with a history of heart failure. Patients who are intolerant to ibrutinib can receive a more selective BTKi. Patients who develop resistance to covalent BTKis can be treated with a non‑covalent BTKi or with a BCL2 inhibitor. BTKis can be administered in combination with an anti‑CD20 monoclonal antibody and/or a BCL2 inhibitor to reduce the proliferation of resistant clones, and sometimes to allow the shortening of the treatment duration. Further developments include Bruton's tyrosine kinase degraders, the combination of BTKis with immune checkpoint inhibitors or chimeric antigen receptor T‑cells, or drugs that target 6,7‑dimethoxy‑N‑(pyridin‑3‑yl)quinazolin‑4‑amine or actin cytoskeleton organization.

View Figures

View References

1	Shadman M: Diagnosis and treatment of chronic lymphocytic leukemia: A review. JAMA. 329:918–932. 2023.PubMed/NCBI View Article : Google Scholar
2	Hampel PJ and Parikh SA: Correction: Chronic lymphocytic leukemia treatment algorithm 2022. Blood Cancer J. 12(172)2022.PubMed/NCBI View Article : Google Scholar
3	Chen SS and Chiorazzi N: Functional consequences of inhibition of Bruton's tyrosine kinase by ibrutinib in chronic lymphocytic leukemia. Hematol Oncol. 41 (Suppl 1):S119–S128. 2023.PubMed/NCBI View Article : Google Scholar
4	Wen T, Wang J, Shi Y, Qian H and Liu P: Inhibitors targeting Bruton's tyrosine kinase in cancers: Drug development advances. Leukemia. 35:312–332. 2021.PubMed/NCBI View Article : Google Scholar
5	Rey-Barroso J, Munaretto A, Rouquié N, Mougel A, Chassan M, Gadat S, Dewingle O, Poincloux R, Cadot S, Ysebaert L, et al: Lymphocyte migration and retention properties affected by ibrutinib in chronic lymphocytic leukemia. Haematologica. 109:809–823. 2024.PubMed/NCBI View Article : Google Scholar
6	Song Y, Zhou K, Yang S, Hu J, Zou D, Gao S, Pan L, Wang T, Yang H, Zhang H, et al: Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma. Invest New Drugs. 41:606–616. 2023.PubMed/NCBI View Article : Google Scholar
7	Rozkiewicz D, Hermanowicz JM, Kwiatkowska I, Krupa A and Pawlak D: Bruton's tyrosine kinase inhibitors (BTKIs): Review of preclinical studies and evaluation of clinical trials. Molecules. 28(2400)2023.PubMed/NCBI View Article : Google Scholar
8	Dhillon S: Tirabrutinib: First approval. Drugs. 80:835–840. 2020.PubMed/NCBI View Article : Google Scholar
9	Seymour C: FDA Approves Pirtobrutinib for Previously Treated CLL/SLL. https://www.onclive.com/view/fda-approves-pirtobrutinib-for-previously-treated-cll-sll. Available on February 21, 2024.
10	Bennett R, Anderson MA and Seymour JF: Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia. J Hematol Oncol. 16(72)2023.PubMed/NCBI View Article : Google Scholar
11	Alu A, Lei H, Han X, Wei Y and Wei X: BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: Mechanisms and clinical studies. J Hematol Oncol. 15(138)2022.PubMed/NCBI View Article : Google Scholar
12	Nakhoda S, Vistarop A and Wang YL: Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. Br J Haematol. 200:137–149. 2023.PubMed/NCBI View Article : Google Scholar
13	Xu W, Zhou K, Wang T, Yang S, Liu L, Hu Y, Zhang W, Ding K, Zhou J, Gao S, et al: Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study. Am J Hematol. 98:571–579. 2023.PubMed/NCBI View Article : Google Scholar
14	Cao XX, Jin J, Fu CC, Yi SH, Zhao WL, Sun ZM, Yang W, Li DJ, Cui GH, Hu JD, et al: Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study. EClinicalMedicine. 52(101682)2022.PubMed/NCBI View Article : Google Scholar
15	Kaptein A, de Bruin G, Emmelot-van Hoek M, van de Kar B, de Jong A, Gulrajani M, Demont D, Covey T, Mittag D and Barf T: Potency and selectivity of BTK inhibitors in clinical development for B-cell malignancies. CLL: Therapy, excluding transplantation: Poster I. Blood. 132 (Suppl 1)(S1871)2018.
16	Robak T, Witkowska M and Smolewski P: The role of Bruton's kinase inhibitors in chronic lymphocytic leukemia: Current status and future directions. Cancers (Basel). 14(771)2022.PubMed/NCBI View Article : Google Scholar
17	Berglöf A, Hamasy A, Meinke S, Palma M, Krstic A, Månsson R, Kimby E, Österborg A and Smith CI: Targets for ibrutinib beyond B cell malignancies. Scand J Immunol. 82:208–217. 2015.PubMed/NCBI View Article : Google Scholar
18	Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, et al: Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 122:2539–2549. 2013.PubMed/NCBI View Article : Google Scholar
19	Montoya S and Thompson MC: Non-covalent bruton's tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Cancers (Basel). 15(3648)2023.PubMed/NCBI View Article : Google Scholar
20	Li L, Su M, Lu W, Song H, Liu J, Wen X, Suo Y, Qi J, Luo X, Zhou YB, et al: Triazine-based covalent DNA-encoded libraries for discovery of covalent inhibitors of target proteins. ACS Med Chem Lett. 13:1574–1581. 2022.PubMed/NCBI View Article : Google Scholar
21	Jensen JL, Mato AR, Pena C, Roeker LE and Coombs CC: The potential of pirtobrutinib in multiple B-cell malignancies. Ther Adv Hematol. 13(20406207221101697)2022.PubMed/NCBI View Article : Google Scholar
22	Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B, Walewska R, Furtado M, Preston G, Neilson JR, et al: Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): Interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 24:535–552. 2023.PubMed/NCBI View Article : Google Scholar
23	Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kaźmierczak M, Lamanna N, O'Brien SM, Tam CS, Qiu L, Zhou K, et al: Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 388:319–332. 2023.PubMed/NCBI View Article : Google Scholar
24	Hillmen P, Eichhorst B, Brown JR, Lamanna N, O'Brien SM, Tam CS, Qiu L, Kazmierczak M, Zhou K, Šimkovič M, et al: Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: Interim analysis of a randomized phase III trial. J Clin Oncol. 41:1035–1045. 2023.PubMed/NCBI View Article : Google Scholar
25	Mato AR, Woyach JA, Brown JR, Ghia P, Patel K, Eyre TA, Munir T, Lech-Maranda E, Lamanna N, Tam CS, et al: Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med. 389:33–44. 2023.PubMed/NCBI View Article : Google Scholar
26	Gill S, Vides V, Frey NV, Hexner EO, Metzger S, O'Brien M, Hwang WT, Brogdon JL, Davis MM, Fraietta JA, et al: Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 6:5774–5785. 2022.PubMed/NCBI View Article : Google Scholar
27	Ghia P, Pluta A, Wach M, Lysak D, Šimkovič M, Kriachok I, Illés Á, de la Serna J, Dolan S, Campbell P, et al: Acalabrutinib versus investigator's choice in relapsed/refractory chronic lymphocytic leukemia: Final ASCEND trial results. Hemasphere. 6(e801)2022.PubMed/NCBI View Article : Google Scholar
28	Nguyen TT, Nhu NT, Tran VK, Nguyen TTH and Lin CF: Efficacy and safety of Bruton tyrosine kinase inhibitor monotherapy compared with combination therapy for chronic lymphocytic leukemia and small lymphocytic lymphoma: A systematic review and meta-analysis. Cancers (Basel). 15(1996)2023.PubMed/NCBI View Article : Google Scholar
29	Lee P, Kistler KD, Douyon L, Volodarsky R, Young A, Karve S and Challagulla S: Systematic literature review of real-world effectiveness results data for first-line ibrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma. Drugs Real World Outcomes. 10:11–22. 2023.PubMed/NCBI View Article : Google Scholar
30	Boriani G, Menna P, Morgagni R, Minotti G and Vitolo M: Ibrutinib and Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death. Chemotherapy. 68:61–72. 2023.PubMed/NCBI View Article : Google Scholar
31	Špaček M, Smolej L, Šimkovič M, Nekvindová L, Křístková Z, Brychtová Y, Panovská A, Mašlejová S, Bezděková L, Écsiová D, et al: Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the chronic lymphocytic leukemia patients registry (CLLEAR). Br J Haematol. 202:40–47. 2023.PubMed/NCBI View Article : Google Scholar
32	Muhowski EM, Ravikrishnan J, Gordon B, Yu L, Misra S, Walker B, Eathiraj S, Sampath D, Rogers KA, Byrd JC and Woyach JA: Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia. J Hematol Oncol. 15(166)2022.PubMed/NCBI View Article : Google Scholar
33	Eyre TA and Riches JC: The evolution of therapies targeting Bruton tyrosine kinase for the treatment of chronic lymphocytic leukaemia: Future perspectives. Cancers (Basel). 15(2596)2023.PubMed/NCBI View Article : Google Scholar
34	Perutelli F, Montalbano MC, Boccellato E, Coscia M and Vitale C: Beyond ibrutinib: Novel BTK inhibitors for the treatment of chronic lymphocytic leukemia. Curr Opin Oncol. 34:757–767. 2022.PubMed/NCBI View Article : Google Scholar
35	Roeker LE, DerSarkissian M, Ryan K, Chen Y, Duh MS, Wahlstrom SK, Hakre S, Yu L, Guo H and Mato AR: Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia. Blood Adv. 7:4291–4301. 2023.PubMed/NCBI View Article : Google Scholar
36	Munir T, Genovez V, Genestier V, Ryan K, Liljas B and Gaitonde P: Cost-effectiveness of acalabrutinib regimens in treatment-naïve chronic lymphocytic leukemia in the United States. Expert Rev Pharmacoecon Outcomes Res. 23:579–589. 2023.PubMed/NCBI View Article : Google Scholar
37	Wallace DS, Zent CS, Baran AM, Reagan PM, Casulo C, Rice G, Friedberg JW and Barr PM: Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia. Blood Adv. 7:2496–2503. 2023.PubMed/NCBI View Article : Google Scholar
38	Podoll T, Pearson PG, Kaptein A, Evarts J, de Bruin G, Emmelot-van Hoek M, de Jong A, van Lith B, Sun H, Byard S, et al: Identification and characterization of ACP-5862, the major circulating active metabolite of acalabrutinib: Both are potent and selective covalent Bruton tyrosine kinase inhibitors. J Pharmacol Exp Ther. 384:173–186. 2023.PubMed/NCBI View Article : Google Scholar
39	Wolska-Washer A and Robak T: Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions. Front Oncol. 13(1130595)2023.PubMed/NCBI View Article : Google Scholar
40	Molica S, Tam C, Allsup D and Polliack A: Advancements in the treatment of CLL: The rise of zanubrutinib as a preferred therapeutic option. Cancers (Basel). 15(3737)2023.PubMed/NCBI View Article : Google Scholar
41	Gu D, Li J and Miao Y: Evaluating orelabrutinib as a novel treatment option for relapsed/refractory chronic lymphocytic leukemia in China. Expert Opin Pharmacother. 23:1979–1986. 2022.PubMed/NCBI View Article : Google Scholar
42	Robak P, Witkowska M, Wolska-Washer A and Robak T: The preclinical discovery and development of orelabrutinib as a novel treatment option for B-cell lymphoid malignancies. Expert Opin Drug Discov. 18:1065–1076. 2023.PubMed/NCBI View Article : Google Scholar
43	Munakata W, Ando K, Yokoyama M, Fukuhara N, Yamamoto K, Fukuhara S, Ohmachi K, Mishima Y, Ichikawa S, Ogiya D, et al: Long-term safety profile of tirabrutinib: final results of a Japanese phase I study in patients with relapsed or refractory B-cell malignancies. Int J Hematol. 117:553–562. 2023.PubMed/NCBI View Article : Google Scholar
44	Wang H, Guo H, Yang J, Liu Y, Liu X, Zhang Q and Zhou K: Bruton tyrosine kinase inhibitors in B-cell lymphoma: Beyond the antitumour effect. Exp Hematol Oncol. 11(60)2022.PubMed/NCBI View Article : Google Scholar
45	Yano M, Nunes J, Mo X, Rogers KA, Woyach JA, Byrd JC and Muthusamy N: Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL. Blood Adv. 6:5440–5448. 2022.PubMed/NCBI View Article : Google Scholar
46	Lee HK, Hoechstetter MA, Buchner M, Pham TT, Huh JW, Müller K, Zange S, von Buttlar H, Girl P, Wölfel R, et al: Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination. Blood Adv. 7:2214–2227. 2023.PubMed/NCBI View Article : Google Scholar
47	Daniel A, Ghez D, Ravaiau C, Cavalieri D, Tournilhac O, Herbaux C, Roriz M, Wemeau M, Guillet S, Bossard JB, et al: Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B-cell lymphoma. Eur J Haematol. 109:719–727. 2022.PubMed/NCBI View Article : Google Scholar
48	Yan Y, Lv R, Wang T, Yu Y, Huang Y, Xiong W, Li Y, Sui W, Wang Q, Huang W, et al: Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China. Front Immunol. 14(1184395)2023.PubMed/NCBI View Article : Google Scholar
49	Sharma S, Pepin X, Burri H, Zheng L, Kuptsova-Clarkson N, de Jong A, Yu T, MacArthur HL, Majewski M, Byrd JC, et al: Bioequivalence and relative bioavailability studies to assess a new acalabrutinib formulation that enables coadministration with proton-pump inhibitors. Clin Pharmacol Drug Dev. 11:1294–1307. 2022.PubMed/NCBI View Article : Google Scholar
50	Karadeniz M, Cinar OE, Erdogdu B, Malkan UY, Goker H and Ozcebe OI: Hypophosphatemia related to the use of ibrutinib. J Oncol Pharm Pract: 10781552231164504, 2023 (Epub ahead of print).
51	Wan Q, Li Q, Lai X, Xu T, Hu J and Peng H: Data mining and safety analysis of BTK inhibitors: A pharmacovigilance investigation based on the FAERS database. Front Pharmacol. 13(995522)2022.PubMed/NCBI View Article : Google Scholar
52	Awan FT, Addison D, Alfraih F, Baratta SJ, Campos RN, Cugliari MS, Goh YT, Ionin VA, Mundnich S, Sverdlov AL, et al: International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL. Blood Adv. 6:5516–5525. 2022.PubMed/NCBI View Article : Google Scholar
53	Gordon MJ, Jones JE, George B, Peterson C, Burger JA, Jain N, Keating M, Wierda WG, Durand JB and Ferrajoli A: Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity. Cancer. 129:2192–2200. 2023.PubMed/NCBI View Article : Google Scholar
54	Seymour JF, Byrd JC, Ghia P, Kater AP, Chanan-Khan A, Furman RR, O'Brien S, Brown JR, Munir T, Mato A, et al: Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 142:687–699. 2023.PubMed/NCBI View Article : Google Scholar
55	Elaskalani O, Gilmore G, Hagger M, Baker RI and Metharom P: Adenosine 2A receptor activation amplifies ibrutinib antiplatelet effect; implications in chronic lymphocytic leukemia. Cancers (Basel). 14(5750)2022.PubMed/NCBI View Article : Google Scholar
56	Tham K, Prelewicz S, deHoll S, Stephens DM and Gomez CA: Infectious complications among patients receiving ibrutinib for the treatment of hematological malignancies. Am J Health Syst Pharm. 81:112–119. 2024.PubMed/NCBI View Article : Google Scholar
57	Diella L, Bavaro DF, Loseto G, Pasciolla C, Minoia C, Di Gennaro D, Belati A, De Candia MS, Di Gennaro F, Saracino A and Guarini A: Current therapies for chronic lymphocytic leukemia: Risk and prophylaxis strategies for secondary/opportunistic infections. Expert Rev Hematol. 16:267–276. 2023.PubMed/NCBI View Article : Google Scholar
58	No authors listed. Correction to: Managing ibrutinib-intolerant patients with B-cell malignancies. Oncologist. 28(e487)2023.PubMed/NCBI View Article : Google Scholar
59	Shadman M, Flinn IW, Levy MY, Porter RF, Burke JM, Zafar SF, Misleh J, Kingsley EC, Yimer HA, Freeman B, et al: Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: A phase 2, open-label, single-arm study. Lancet Haematol. 10:e35–e45. 2023.PubMed/NCBI View Article : Google Scholar
60	Salmerón-Navas FJ, Barreiro-Fernández EM and Fénix-Caballero S: Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia. Farm Hosp. 48:9–15. 2024.PubMed/NCBI View Article : Google Scholar
61	Chen S, Wei Y, Li S, Miao Y, Gu J, Cui Y, Liu Z, Liang J, Wei L, Li X, et al: Zanubrutinib attenuates bleomycin-induced pulmonary fibrosis by inhibiting the TGF-β1 signaling pathway. Int Immunopharmacol. 113(109316)2022.PubMed/NCBI View Article : Google Scholar
62	Blombery P, Thompson ER, Lew TE, Tiong IS, Bennett R, Cheah CY, Lewis KL, Handunnetti SM, Tang CPS, Roberts A, et al: Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: Potential for pirtobrutinib cross-resistance. Blood Adv. 6:5589–5592. 2022.PubMed/NCBI View Article : Google Scholar
63	Naeem A, Utro F, Wang Q, Cha J, Vihinen M, Martindale S, Zhou Y, Ren Y, Tyekucheva S, Kim AS, et al: Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance. Blood Adv. 7:1929–1943. 2023.PubMed/NCBI View Article : Google Scholar
64	Takács F, Kotmayer L, Czeti Á, Szalóki G, László T, Mikala G, Márk Á, Masszi A, Farkas P, Plander M, et al: Revealing a phenotypical appearance of ibrutinib resistance in patients with chronic lymphocytic leukaemia by flow cytometry. Pathol Oncol Res. 28(1610659)2022.PubMed/NCBI View Article : Google Scholar
65	Maher N, Mouhssine S, Matti BF, Alwan AF and Gaidano G: Treatment refractoriness in chronic lymphocytic leukemia: Old and new molecular biomarkers. Int J Mol Sci. 24(10374)2023.PubMed/NCBI View Article : Google Scholar
66	Woyach JA, Ghia P, Byrd JC, Ahn IE, Moreno C, O'Brien SM, Jones D, Cheung LWK, Chong E, Kwei K, et al: B-cell receptor pathway mutations are infrequent in patients with chronic lymphocytic leukemia on continuous ibrutinib therapy. Clin Cancer Res. 29:3065–3073. 2023.PubMed/NCBI View Article : Google Scholar
67	Alsadhan A, Chen J, Gaglione EM, Underbayev C, Tuma PL, Tian X, Freeman LA, Baskar S, Nierman P, Soto S, et al: CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy. Clin Cancer Res. 29:3612–3621. 2023.PubMed/NCBI View Article : Google Scholar
68	Tissino E, Bomben R, Gattei V and Zucchetto A: BCR/integrin interaction in CLL: A physiologic remnant with clinical relevance. Clin Cancer Res. 29:3560–3562. 2023.PubMed/NCBI View Article : Google Scholar
69	Thompson PA and Tam CS: Pirtobrutinib: A new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders. Blood. 141:3137–3142. 2023.PubMed/NCBI View Article : Google Scholar
70	Chung C, Umoru G, Abboud K and Hobaugh E: Sequencing and combination of current small-molecule inhibitors for chronic lymphocytic leukemia: Where is the evidence? Eur J Haematol. 111:15–28. 2023.PubMed/NCBI View Article : Google Scholar
71	Rizzuto A, Pirrera A, Gigliotta E, Mancuso S, Vullo C, Camarda GM, Rotolo C, Roppolo A, Spoto C, Gentile M, et al: Molecular-biology-driven frontline treatment for chronic lymphocytic leukemia: A network meta-analysis of randomized clinical trials. Int J Mol Sci. 24(9930)2023.PubMed/NCBI View Article : Google Scholar
72	Nguyen TT, Thanh Nhu N, Tran VK, Van Cau N and Lin CF: Efficacy and safety of Bruton tyrosine kinase inhibitor plus anti-CD20 antibody therapy compared with chemoimmunotherapy as front-line treatment for chronic lymphocytic leukemia: A systematic review and meta-analysis of randomized controlled trials. J Immunother. 46:299–309. 2023.PubMed/NCBI View Article : Google Scholar
73	Nguyen TT, Nhu NT, Tran VK, Viet-Nhi NK, Ho XD, Jhan MK, Chen YP and Lin CF: Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: A meta-analysis. Sci Rep. 13(9775)2023.PubMed/NCBI View Article : Google Scholar
74	Scarfò L, Heltai S, Albi E, Scarano E, Schiattone L, Farina L, Moia R, Deodato M, Ferrario A, Motta M, et al: Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL. Blood. 140:2348–2357. 2022.PubMed/NCBI View Article : Google Scholar
75	Cervantes-Gomez F, Lamothe B, Woyach JA, Wierda WG, Keating MJ, Balakrishnan K and Gandhi V: Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia. Clin Cancer Res. 21:3705–3715. 2015.PubMed/NCBI View Article : Google Scholar
76	Godwin CD, Bates OM, Garling EE, Beddoe ME, Laszlo GS and Walter RB: The Bruton's tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity. Br J Haematol. 189:e9–e13. 2020.PubMed/NCBI View Article : Google Scholar
77	Mhibik M, Gaglione EM, Eik D, Kendall EK, Blackburn A, Keyvanfar K, Baptista MJ, Ahn IE, Sun C, Qi J, et al: BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL. Blood. 138:1843–1854. 2012.PubMed/NCBI View Article : Google Scholar
78	Nasnas P, Cerchione C, Musuraca G, Martinelli G and Ferrajoli A: How I manage chronic lymphocytic leukemia. Hematol Rep. 15:454–464. 2023.PubMed/NCBI View Article : Google Scholar
79	Easaw S, Ezzati S and Coombs CC: SOHO State of the art updates and next questions: Updates on BTK inhibitors for the treatment of chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 23:697–704. 2023.PubMed/NCBI View Article : Google Scholar
80	Kim T, Kim K, Park I, Hong S and Park H: Two-track virtual screening approach to identify the dual inhibitors of wild type and C481S mutant of Bruton's tyrosine kinase. J Chem Inf Model. 62:4500–4511. 2022.PubMed/NCBI View Article : Google Scholar
81	Thus YJ, De Rooij MFM, Beijersbergen RL and Spaargaren M: An Unbiased CRISPR-Cas9 screening method for the identification of positive and negative regulatory proteins of cell adhesion. Bio Protoc. 12(e4545)2022.PubMed/NCBI View Article : Google Scholar
82	Mihăilă RG and Topîrcean D: The high-performance technology CRISPR/Cas9 improves knowledge and management of acute myeloid leukemia. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 165:249–257. 2021.PubMed/NCBI View Article : Google Scholar
83	Sampietro M, Cassina V, Salerno D, Barbaglio F, Buglione E, Marrano CA, Campanile R, Scarfò L, Biedenweg D, Fregin B, et al: The nanomechanical properties of CLL cells are linked to the actin cytoskeleton and are a potential target of BTK inhibitors. Hemasphere. 7(e931)2023.PubMed/NCBI View Article : Google Scholar